Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Cardiometabolic Risk Factors: Greater improvements in cardiometabolic risk factors compared to those taking a placebo
Moosavian et al., 2023)
Finding #2: More Noom app use = over 25% more weight loss at 40 weeks Rigorous studies have shown that higher levels of engagement in the Noom app drive higher weight loss, but what about for members on GLP-1 medication
These agents include semaglutide (Ozempic for diabetes, Wegovy for obesity), liraglutide (Victoza for diabetes, Saxenda for obesity), dulaglutide (Trulicity, diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for obesity)with tirzepatide being a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist
Its regenerative properties extend to cardiovascular health, where it aids in tissue repair and may help reduce the risk of cardiovascular disease
doi:10.21203/rs.3.rs-122457/v1 164
:max_bytes(150000):strip_icc()/26Q1_WL_oral-sema_newsroom_1920x1008-1dfa18327b724266bed50c36ab0b9d49.jpg)
